Characteristic | HT group (n = 59) | MCT group (n = 79) | P value |
---|---|---|---|
Age (years)a | Â | Â | 0.009 (t test) |
Median | 49 | 50 | Â |
 Range | 37–76 | 34–66 |  |
KPS score | Â | Â | 0.349 |
 90–100 | 46 (78.0) | 56 (70.9) |  |
 70–80 | 13 (22.0) | 23 (29.1) |  |
Menopausal status | Â | Â | 0.520 |
 Premenopausal | 20 (33.9) | 31 (39.2) |  |
 Postmenopausal | 39 (66.1) | 48 (60.8) |  |
HR status | Â | Â | Â |
 ER-positive | 55 (93.2) | 73 (92.4) | 0.855 |
 PgR-positive | 51 (86.4) | 65 (82.2) | 0.509 |
Adjuvant HT | Â | Â | 0.246 |
 Yes | 50 (84.7) | 72 (91.1) |  |
 No | 9 (15.3) | 7 (8.9) |  |
DFS (years) | Â | Â | 0.446 |
 <2 | 16 (27.1) | 17 (21.5) |  |
 ≥2 | 43 (72.9) | 62 (78.5) |  |
 Mediana (months) | 44 | 42 | 0.178 (t test) |
No. of metastases | Â | Â | 0.006 |
 <2 | 30 (50.9) | 22 (27.9) |  |
 ≥2 | 29 (49.1) | 57 (72.1) |  |
Metastatic sites | Â | Â | 0.168 |
 Viscera | 32 (54.2) | 52 (65.8) |  |
 Non-viscera | 27 (45.8) | 27 (34.2) |  |
Prior adjuvant CT | Â | Â | Â |
 Anthracycline | 54 (91.5) | 70 (88.6) | 0.749 |
 Taxanes | 32 (54.2) | 53 (67.1) | 0.170 |
Response to FCCT | Â | Â | 0.009 |
 CR + PR | 28 (47.4) | 55 (69.6) |  |
 SD | 31 (52.3) | 24 (30.4) |  |